Additionally, in human malignant mesothelioma xenograft mouse models, treatment with AmatuxEDVDox led to statistically significant suppression of tumour growth, measured by both tumour size and a reduction in nuclear staining of excised tumour by Ki67, an antibody which recognizes a marker of cell cycle proliferation [44–46]. Here, MKI67 is linked to malignant mesothelioma.